-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, RNkYk7oE4XLfn3nTunyhaULFK6+Ms04ljlkroCYwtIn4mgPcUeGbo0SpVn6uFjp+ rAvqbJrF0JyMfpi5JhcT8g== 0000950123-10-106827.txt : 20101118 0000950123-10-106827.hdr.sgml : 20101118 20101118060313 ACCESSION NUMBER: 0000950123-10-106827 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20101118 ITEM INFORMATION: Other Events FILED AS OF DATE: 20101118 DATE AS OF CHANGE: 20101118 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Valeant Pharmaceuticals International, Inc. CENTRAL INDEX KEY: 0000885590 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: A6 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-14956 FILM NUMBER: 101201199 BUSINESS ADDRESS: STREET 1: 7150 MISSISSAUGA ROAD STREET 2: MISSISSAUGA CITY: ONTARIO STATE: A6 ZIP: 00000 BUSINESS PHONE: 905 286-3000 MAIL ADDRESS: STREET 1: 7150 MISSISSAUGA ROAD STREET 2: MISSISSAUGA CITY: ONTARIO STATE: A6 ZIP: 00000 FORMER COMPANY: FORMER CONFORMED NAME: BIOVAIL Corp DATE OF NAME CHANGE: 20100416 FORMER COMPANY: FORMER CONFORMED NAME: BIOVAIL CORP INTERNATIONAL DATE OF NAME CHANGE: 19960522 8-K 1 a57899e8vk.htm FORM 8-K e8vk
Table of Contents

 
 
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
 
FORM 8-K
 
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
DATE OF REPORT (Date of earliest event reported): November 18, 2010 (November 18, 2010)
 
Valeant Pharmaceuticals International, Inc.
(Exact name of registrant as specified in its charter)
 
         
Canada   001-14956   98-0448205
(State or other jurisdiction of incorporation)   (Commission File Number)   (I.R.S. Employer Identification No.)
         
7150 Mississauga Road        
Mississauga, Ontario        
Canada       L5N 8M5
(Address of principal executive offices)       (Zip Code)
(905) 286-3000
(Registrant’s telephone number, including area code)
 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
o   Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o   Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o   Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o   Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
 
 

 

TABLE OF CONTENTS

Item 8.01 Other Events.
Signatures

Table of Contents

Item 8.01   Other Events.
Valeant Pharmaceuticals International, Inc. (the “Company”) is supplementing the information in the section entitled “Management’s Discussion and Analysis of Financial Condition and Results of Operations” contained in the Company’s Quarterly Report on Form 10-Q for the period ended September 30, 2010 as follows:
Concurrent with the acquisition of Valeant Pharmaceuticals International (“Valeant”) and its subsidiaries by the Company on September 28, 2010, Valeant issued $500.0 million aggregate principal amount of 6.75% senior notes due October 1, 2017, and $700.0 million aggregate principal amount of 7.00% senior notes due October 1, 2020 (collectively, the “Senior Notes”) in a private placement. The Senior Notes are guaranteed on a senior unsecured basis by the Company and certain of its material subsidiaries (other than Valeant) as set forth in the Senior Notes Indenture (the “Non-Guarantor Subsidiaries”). The Non-Guarantor Subsidiaries had total assets of $3,471.9 million and total liabilities of $792.2 million as of September 30, 2010, and net revenues of $18.4 million and income from operations of $5.2 million for the nine months ended September 30, 2010. These amounts are provisional and subject to change, pending finalization by the Company of the measurement process related to the acquired assets and assumed liabilities of Valeant and its subsidiaries as of the date of acquisition. These changes could be significant.

 

Table of Contents

Signatures
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
     
 
  VALEANT PHARMACEUTICALS
 
  INTERNATIONAL, INC.,
 
    
 
  By: /s/ Robert Chai-Onn
 
    
 
  Name: Robert Chai-Onn
 
    
 
  Title: Executive Vice President,
 
  General Counsel and Corporate
 
  Secretary
November 18, 2010

 

-----END PRIVACY-ENHANCED MESSAGE-----